[Intra-abdominal administration of CDDP in the management of carcinomatous peritonitis].
Seven patients with carcinomatous peritonitis were intraperitoneally treated with CDDP. This procedure does not require specific hydration transfusion and much less diuretic. According to Koyama and Saito's criteria, one patient showed complete response, 5 showed partial response and one no change. Following this therapy, 4 patients have lived for more than 6 months. Renal toxicity, which is considered to be the most serious side effect of CDDP, was not found. Alimentary symptoms (nausea, vomiting) were noted in all patients and myelosuppression and abdominal bleeding were recognized in a small number of patients. In conclusion, our method is considered to be advantageous in the treatment of carcinomatus peritonitis.
D000328:Adult; D002945:Cisplatin / Q000008:administration & dosage* / Q000627:therapeutic use; D003907:Dexamethasone / Q000008:administration & dosage; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010529:Peritoneal Cavity; D010538:Peritonitis / Q000188:drug therapy* / Q000209:etiology; D013274:Stomach Neoplasms / Q000150:complications / Q000188:drug therapy*
D003907:Dexamethasone; D002945:Cisplatin